2024-02-12 09:00:07 ET
The U.S. IPO market is slowly reviving after a two-year pause that has been attributed to an aggressive tightening cycle by the Federal Reserve and geopolitical uncertainty. Drug developers have scored recent wins, as seen with the successful IPOs of Kyverna Therapeutics ( NASDAQ: KYTX ) and CG Oncology ( NASDAQ: CGON ), highlighting the growing demand for healthcare innovations and investment opportunities in the sector. The Renaissance IPO ETF ( NYSEARCA: IPO ) is still down nearly 2% YTD, trailing the S&P 500, which recently topped the 5,000-point milestone and has gained at least 5.4% during the same period....
Read the full article on Seeking Alpha
For further details see:
IPO Roundup: Wetouch Technology, Amphitrite Digital, and more